
浏览全部资源
扫码关注微信
纸质出版日期:2011
移动端阅览
马燕, 张晶, 王亚, 等. 黄芪降糖颗粒降糖作用实验研究[J]. 中国实验方剂学杂志, 2011,17(8):157-160.
MA Yan, ZHANG Jing, WANG Ya, et al. Experimental Study on Hypoglycemic Effect of Astragalus Hypoglycemic Granule[J]. Chinese journal of experimental traditional medical formulae, 2011, 17(8): 157-160.
目的: 观察黄芪降糖颗粒对链脲佐菌素(STZ)所致的2型糖尿病小鼠的降糖作用。 方法: 80只SPF级雄性C57BL/6小鼠
4~5周龄
维持饲料喂养1周
按随机数字表法
随机抽取10只作为正常组
其余70只采用KK饲料喂养加60 mg ·kg-1的STZ ip诱导糖尿病
造模成功60只。随机分为黄芪降糖颗粒低、中、高剂量组(1.0
2.0
3.0 g ·kg-1)
盐酸二甲双胍片组(0.3 g ·kg-1)、参芪降糖颗粒组(0.2 g ·kg-1)、模型组
每组各10只。各组ig给药
正常组与模型组给同体积蒸馏水
每日1次
连续14 d。观察黄芪降糖颗粒对小鼠空腹血糖(FBG)、体重(Weight)、血清胰岛素(Ins)的影响及胰岛β细胞病理改变情况。 结果: 各治疗组均能明显降低2型糖尿病小鼠的空腹血糖
增加血清胰岛素含量
有效控制小鼠体重降低
改善胰岛β细胞损坏。与模型组的空腹血糖、血清胰岛素和体重值(28.88±6.79) mmol ·L-1
(9.69±2.66) mU ·L-1
(20.00±1.18)g比较
黄芪降糖颗粒高剂量组(13.20±2.02) mmol ·L-1
(18.98±1.41) mU ·L-1
(26.08±0.63) g和盐酸二甲双胍片组(13.40±1.92) mmol ·L-1
(17.33±1.23) mU ·L-1
(25.83±0.89) g均有显著差异(P<0.01)
黄芪降糖颗粒低剂量组(19.35±2.02)mmol ·L-1
(15.89±1.38) mU ·L-1
(25.69±0.44) g和参芪降糖颗粒组(20.38±1.93) mmol ·L-1
(15.80±1.21) mU ·L-1
(22.90±0.74)g均有统计学意义(P<0.05)。 结论: 黄芪降糖颗粒能明显降低2型糖尿病小鼠的空腹血糖
增加血清胰岛素含量
对胰岛β细胞具有修复作用。
Objective: To observe the hypoglycemic effect of the Astragalus Hypoglycemic Granule on type 2 diabetic mice caused by streptozotocin(STZ). Method: Eighty SPF male C57BL/6 mice of 4-5 weeks old were given the diet of maintenance fodder for one week. After that 10 mice were selected randomly to form the normal group. Given high fat forage diet and intraperitoneal injection of STZ of 60 mg ·kg-1
type 2 diabetic model was established for the other 60 mice. Then
they were randomly divided into low dose of Astragalus Hypoglycemic Granule group(1.0 g ·kg-1)
middle dose of Astragalus Hypoglycemic Granule group(2.0 g ·kg-1)
high dose of Astragalus Hypoglycemic Granule group(3.0 g ·kg-1)
metformin hydrochloride group(0.3 g ·kg-1)
Ginseng-Astragalus Hypoglycemic Granule group(0.2 g ·kg-1)
and model control group(n=10 in each group). The mice in normal and model control groups were given distilled water once a day and the ones in other groups were administrated medicine treatment by ig once a day for 14 days. The changes regarding fasting blood glucose(FBG)
body weight
serum insulin and pathological changes in β-Islet-cells were observed after continuous 14 days’ medical administration of Astragalus Hypoglycemic Granule. Result: FBG was decreased significantly
the content of serum insulin was increased obviously
the body weight was controlled effectively and the damage of β-Islet-cells was repaired in type 2 diabetic mice of each group after medicine administration. Compared with the mice in model control group ·L-1
serum insulin:(9.69±2.66) mU ·L-1
weight:(20.00±1.18)g]
there were significant difference with the mice in high dose of Astragalus Hypoglycemic Granule group ·L-1
serum insulin:(18.98±1.41) mU ·L-1
weight:(26.08±0.63)g] and the mice in metformin hydrochloride group ·L-1
serum insulin:(17.33±1. 23) mU ·L-1
weight:(25.83±0.89)g](P<0.01). There showed statistical significance in the mice of low dose of Astragalus Hypoglycemic Granule group ·L-1
serum insulin:(15.89±1.38)mU ·L-1
weight:(25.69±0.44) g] and the mice in Ginseng-Astragalus Hypoglycemic Granule group ·L-1
serum insulin:(15.80±1.21) mU ·L-1
weight:(22.90±0.74) g](P<0.05). Conclusion: Astragalus Hypoglycemic Granule can significantly decrease fast blood glucose
increase the content of serum insulin and has repair function for β-islet-cells.
0
浏览量
2
下载量
0
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621